Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Trace Matters is a private analytical instrumentation company developing next-generation mass spectrometry technologies. Its core offerings include SUPER Mass Spec, a parallelized mass spectrometer architecture designed to improve sensitivity, scan speed, and dynamic range, and SPion Link, a workflow technology that connects mass spectrometers directly to liquid handling systems for automated sample analysis. The company positions these platforms for demanding applications across research and industry, including clinical sample analysis, proteomics, biomarker discovery, and personalized medicine workflows. Although it is not a drug developer, its technologies are relevant to life science and healthcare research because they support analysis of complex biological samples such as tissue and blood.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Trace Matters Scientific.